Watson Pharmaceuticals News

Debiopharm Group , a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced that the New Drug Application for the 6 month ...

Plans by Putnam County's second-largest private employer to relocate remain on track despite some who are interpreting a heightened workload as a possibly hopeful sign.

Corona-based specialty drug maker Watson Pharmaceuticals this morning reported earnings of $71.1 million for its third quarter ending Sept.

Fitch Affirms Watson Pharmaceuticals' IDR at 'BBB-'; Outlook Stable Comtex CHICAGO, Oct 27, 2008 ----Fitch has affirmed Watson Pharmaceuticals, Inc.'s ratings as follows: --Issuer Default Rating at 'BBB-'; ...

Two drug manufacturers are battling in court over a skin patch used to treat bladder problems.

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its subsidiary Watson Laboratories, Inc.

Watson Pharmaceuticals Inc. won U.S. approval to sell a prostate enlargement treatment as the drugmaker expands beyond manufacturing generic medicines.

Watson Pharmaceuticals Inc. announced Wednesday evening that FDA had approved the marketing of silodosin, or Rapaflo, to treat the signs and symptoms of benign prostatic hyperplasia.

The U.S. Food and Drug Administration has given the go ahead to Corona-based Watson Pharmaceuticals Inc.

The data from the open-label, randomised studies in healthy men and women showed that showering one hour or later, or the application of sunscreen 30 minutes before or after OTG application did not ...

Kissei Pharmaceutical Co. , a Japanese drugmaker, rose the most in more than eight years in Tokyo trading after U.S. regulators approved one of its prostate treatments for sale.

Watson Receives US FDA Approval for RAPAFLO for the Treatment of Benign Prostatic Hyperplasia Comtex CORONA, Calif., Oct 08, 2008 /PRNewswire-FirstCall via COMTEX/ ----Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that investigators presented clinical pharmacokinetic data on oxybutynin chloride topical gel , its investigational ...

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today confirmed the receipt of a Paragraph IV Certification Notice Letter relating to an Abbreviated New Drug Application submitted to ...

Some companies are obviously great investments -- in hindsight. Yet for every stock out there screaming " buy me ," others simply give us a nudge and a nod.

Your browser's security settings are preventing some features from appearing. See instructions for fixing the problem.

Negative publicity is something most companies should avoid. But if you are a pharmaceutical company and the negative publicity is about one of your drugs, well, that can be a problem.

When a company stumbles, it's often a great opportunity for competitors to step in and fill the void.

Kinex Pharmaceuticals announced that David Hsia, Ph.D. has been appointed to the Company's Board of Directors.

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced a change to its presentation time at the Morgan Stanley Global Healthcare Unplugged Conference that is being held on ...